PURPOSE: The Dukes stage is used to stratify colorectal cancer patients into groups of different prognosis and need of adjuvant radiotherapy and chemotherapy. However, approximately 80% of patients with Dukes stage C colorectal cancer receive cytotoxic therapy without any expected benefit, for such patients would either not relapse without adjuvant therapy or they would inevitably do so because of tumor resistance to the available regimens. On the other hand, as 20% of Dukes stage B patients would relapse after surgery, adjuvant therapy could improve their survival. Improvement of the Dukes stage predictive accuracy is necessary to better assign patients for adjuvant therapies, especially nowadays when antiangiogenic agents are being incorporated in the clinical practice. PATIENTS AND METHODS: In this study, we examined the prognostic role of Dukes staging system in parallel with three vasculature-related variables (vascular invasion, tumor angiogenic activity, and vascular survival ability) in a series of 130 stage B/C patients with colorectal cancer treated with surgery alone (without adjuvant radiotherapy or chemotherapy). RESULTS: Inclusion of vasculature-related variables in the Dukes staging system significantly improved the prognostic categorization of patients, identifying subgroups of B-stage and C-stage patients with an up to 40% and 60% 5-year survival difference, respectively. CONCLUSIONS: Preliminary results show that the prognostic value of Dukes staging system is significantly improved after taking into account vasculature-related variables, which may be useful in stratifying patients for adjuvant therapies, highlighting also subgroups that may benefit the most from antiangiogenic agents.
PURPOSE: The Dukes stage is used to stratify colorectal cancerpatients into groups of different prognosis and need of adjuvant radiotherapy and chemotherapy. However, approximately 80% of patients with Dukes stage C colorectal cancer receive cytotoxic therapy without any expected benefit, for such patients would either not relapse without adjuvant therapy or they would inevitably do so because of tumor resistance to the available regimens. On the other hand, as 20% of Dukes stage B patients would relapse after surgery, adjuvant therapy could improve their survival. Improvement of the Dukes stage predictive accuracy is necessary to better assign patients for adjuvant therapies, especially nowadays when antiangiogenic agents are being incorporated in the clinical practice. PATIENTS AND METHODS: In this study, we examined the prognostic role of Dukes staging system in parallel with three vasculature-related variables (vascular invasion, tumor angiogenic activity, and vascular survival ability) in a series of 130 stage B/C patients with colorectal cancer treated with surgery alone (without adjuvant radiotherapy or chemotherapy). RESULTS: Inclusion of vasculature-related variables in the Dukes staging system significantly improved the prognostic categorization of patients, identifying subgroups of B-stage and C-stage patients with an up to 40% and 60% 5-year survival difference, respectively. CONCLUSIONS: Preliminary results show that the prognostic value of Dukes staging system is significantly improved after taking into account vasculature-related variables, which may be useful in stratifying patients for adjuvant therapies, highlighting also subgroups that may benefit the most from antiangiogenic agents.
Authors: Ali Aktekin; Selvinaz Özkara; Günay Gürleyik; Mehmet Odabaşi; Tolga Müftüoğlu; Abdullah Sağlam Journal: Indian J Surg Date: 2013-01-26 Impact factor: 0.656
Authors: Susanne K Pedersen; Rohan T Baker; Aidan McEvoy; David H Murray; Melissa Thomas; Peter L Molloy; Sue Mitchell; Trevor Lockett; Graeme P Young; Lawrence C LaPointe Journal: PLoS One Date: 2015-04-30 Impact factor: 3.240
Authors: L Bazzola; C Foroni; D Andreis; V Zanoni; M R Cappelletti; G Allevi; S Aguggini; C Strina; M Milani; S Venturini; F Ferrozzi; R Giardini; R Bertoni; H Turley; K Gatter; P G Petronini; S B Fox; A L Harris; M Martinotti; A Berruti; A Bottini; A R Reynolds; D Generali Journal: Br J Cancer Date: 2014-12-02 Impact factor: 7.640
Authors: Ki Ung Jang; Chan Wook Kim; Ki-Hun Kim; Seok-Byung Lim; Chang Sik Yu; Tae Won Kim; Pyo Nyun Kim; Jong Hoon Kim; Jin Cheon Kim Journal: Ann Coloproctol Date: 2016-06-30
Authors: A Giatromanolaki; M I Koukourakis; E Sivridis; K C Gatter; T Trarbach; G Folprecht; M M Shi; D Lebwohl; T Jalava; D Laurent; G Meinhardt; A L Harris Journal: Br J Cancer Date: 2012-08-21 Impact factor: 7.640
Authors: Yi Huang; Hai Huang; Xiu-Wu Pan; Dan-Feng Xu; Xin-Gang Cui; Jie Chen; Yi Hong; Yi Gao; Lei Yin; Jian-Qing Ye; Lin Li Journal: Asian J Androl Date: 2016 Sep-Oct Impact factor: 3.285